Genetic Technologies Ltd. (GENE)
| Market Cap | 58.82M |
| Revenue (ttm) | 6,803 |
| Net Income (ttm) | -4.21M |
| Shares Out | 15.03M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $3.56 |
| Previous Close | $3.61 |
| Change ($) | -0.05 |
| Change (%) | -1.39% |
| Day's Open | 3.64 |
| Day's Range | 3.51 - 3.64 |
| Day's Volume | 125,975 |
| 52-Week Range | 2.77 - 8.18 |
Genetic Technologies Limited (NASDAQ: GENE) has agreed to acquire EasyDNA's brand and distribution rights from BelHealth for $4 million in cash and stock. EasyDNA currently sells paternity, oncology, an...
A global platform to market the Company's portfolio across 40 countries A global platform to market the Company's portfolio across 40 countries
MELBOURNE, Australia, July 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE, "Company", "GTG"), a diversified Genomics and AI driven preventative health business, today ...
MELBOURNE, Australia, June 11, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, has be...
PISCATAWAY, N.J.--(BUSINESS WIRE)-- #covid19--Today, Infinity BiologiX (IBX) announces the launch of a new test meant to assess the severity of COVID-19 in individuals. The COVID-19 Risk Test is designe...
MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, today a...
MELBOURNE, Australia, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), announces the appointment of Michael Tonroe to th...
MELBOURNE, Australia, April 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business provid...
Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
MELBOURNE, Australia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announc...
Genetic Technologies Limited (GENE) Acting CEO George Muchnicki on Quarterly Investor Webinar Transcript
MELBOURNE, Australia, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announc...
Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone...
MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announc...
Shares of GENE stock are rising on Thursday morning after Genetic Technologies provided a positive update regarding two important initatives. The post GENE Stock Alert: 10 Things to Know About Genetic T...
MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on fur...
MELBOURNE, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce an interview with its interi...
MELBOURNE, Australia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy M...
MELBOURNE, Australia, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on the dev...
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ:GENE) (“Genetic Technologies” or the "Company") is developing a Po...
MELBOURNE, Australia, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”) is delighted to announce that initial sales of its G...
MELBOURNE, Australia, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, is pleased...
MELBOURNE, Australia, July 20, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today annou...
MELBOURNE, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today annou...
MELBOURNE, Australia, June 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its interim-CEO ...
MELBOURNE, Australia, May 28, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announ...
MELBOURNE, Australia, May 26, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announ...
MELBOURNE, Australia, May 22, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) provides the following operational updates:
MELBOURNE, Australia, May 20, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an ...
Temporary transition to high throughput COVID-19 testing Temporary transition to high throughput COVID-19 testing
MELBOURNE, Australia, April 06, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today anno...
Genetic Tech (GENE) news for Wednesday includes GENE stock falling after the release of consumer tests for breast and colorectal cancer.
MELBOURNE, Australia, April 01, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today anno...
MELBOURNE, Australia, April 01, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market.
MELBOURNE, Australia, March 13, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today ann...
MELBOURNE, Australia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation breast cancer...
MELBOURNE, Australia, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce the full commissioning of its Australian Laboratory for ...
MELBOURNE, Australia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an update to shar...
Genetic Technologies Limited (NYSE: GENE), a provider of world-leading genetic risk assessment test products today announced that it has signed a 3-year Collaboration Agreement with TGen.
About GENE
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the comp... [Read more...]
| Industry Diagnostics & Research | Founded 1989 |
| Stock Exchange NASDAQ | Ticker Symbol GENE |
Financial Performance
In 2020, GENE's revenue was 9,864, a decrease of -61.23% compared to the previous year's 25,444. Losses were -6.10 million, -5.08% less than in 2019.